Abstract Details

Title Ambulatory Health Care Visits for Epilepsy in the United States in 2006-2008

Topic Epilepsy

Presentation(s) P03 - (-)

Poster/Presentation
Number 116

Objective

Background BACKGROUND: There is very little information on the pattern of ambulatory health care visit among epilepsy patients in the United States.

Design/Methods DESIGN/METHODS: Epilepsy (both primary and secondary diagnoses) visits from the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS) from 2006 to 2008 were analyzed. All estimates have been adjusted using weights provided by the National Center for Health Statistics (NCHS) to account for the multi-stage sampling design of the NAMCS and the NHAMCS.

Results RESULTS: There were an estimated 6.96 million epilepsy patient visits to the physicians' offices and hospital outpatient departments during 2006 - 2008. Overall, 88% of epilepsy patients visited physicians' offices, with 12% visiting hospital outpatient departments. Epilepsy visits per 1000 persons during 2006-2008 were 23. Among the 6.1 million epilepsy visits to the physicians' offices, the top 3 specialties being visited were neurology (54%), General/Family practice (21%), and Internal medicine (10%). 57% of all epilepsy visits were made by females. 14% of all epilepsy visits were made by African-Americans. 37% of all epilepsy visits were paid by private insurance, Medicare covered 25% and Medicaid covered 25% of all visits. Top co-morbidities for epilepsy visits included hypertension, Diabetes, Depression, Arthritis, Hyperlipidemia, cerebrovascular disease, cancer. When comparing epilepsy patients in physicians' offices and hospital outpatient departments, epilepsy patients with Medicaid were more likely to visit hospital outpatient departments than privately insured patients (p=0.02). African-American patients accounted for a disproportionately large percentage of hospital outpatient department visits (p=0.007).

Conclusions CONCLUSIONS: Our study describes the current national pattern of ambulatory health care visits among patients with epilepsy.

Authors/Disclosures
Wenyu Sun, MD (FDA) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ)	Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clario.
Paul B. Pritchard III, MD (Medical University of South Carolina)	No disclosure on file

��ɫ��

��ɫ��